Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 13/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GCK | P35557 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154592 | 0.84 | CA1 (0.55) | SCN3ASCN9ALMNASMN1; SMN2MEN1 | |
| SCHEMBL15913848 | 0.83 | SCN3A (0.53) | SCN3ASCN9ALMNASMN1; SMN2MEN1 | |
| SCHEMBL3160292 | 0.81 | SCN3A (0.52) | SCN3ASCN9ALMNASMN1; SMN2KMT2A | |
| SCHEMBL3154168 | 0.79 | SCN9A (0.46) | SCN3ASCN9AALDH1A1 | |
| SCHEMBL3158753 | 0.77 | SCN9A (0.49) | SCN3ASCN9ALMNAMEN1KMT2A | |
| SCHEMBL3159627 | 0.75 | SCN9A (0.58) | SCN3ASCN9A | |
| SCHEMBL3051038 | 0.75 | SCN9A (0.51) | SCN3ASCN9ALMNAMEN1KMT2A | |
| SCHEMBL29835206 | 0.74 | SCN9A (0.54) | SCN3ASCN9A | |
| SCHEMBL3159074 | 0.74 | SCN9A (0.47) | SCN3ASCN9ALMNAALDH1A1 | |
| SCHEMBL3060924 | 0.73 | SCN3A (0.57) | SCN3ASCN9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338608-B2 | Inhibitors of ion channels | ICAGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705158-B2 | Inhibitors of ion channels | ICAGEN, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | ICAGEN (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | SCN3A 13/4885SCN9A 51/4885LMNA 3442/4885 |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | SCN3A 13/4885SCN9A 51/4885LMNA 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.